Future directions in aerosol therapy

Respiratory Care Clinics of North America

Volumn 7, Issue 2, 2001, Pages 319-335

  Dhand, Rajiv ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA INTERFERON; CALCITONIN; CHLOROFLUOROCARBON; CYCLOSPORIN; DNA; GLUCAGON; GROWTH HORMONE; HEPARIN; INSULIN; INTERLEUKIN DERIVATIVE; LEUPRORELIN; MORPHINE; PARATHYROID HORMONE; PEPTIDE DERIVATIVE; PROTEIN DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TESTOSTERONE;

AEROSOL; ARTICLE; BIOTECHNOLOGY; BREATHING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDICATION; DRUG RELEASE; DRUG SAFETY; GENE THERAPY; HUMAN; PROSPECTIVE STUDY; RESPIRATORY CARE;

EID: 0035171522     PISSN: 10785337     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-5337(05)70036-8     Document Type: Article

References (81)

1. Pulmonary delivery of therapeutic peptides and proteins
2. Gene therapy for lung disease: Hype or hope?
3. Safety of propellants
4. Acute safety of beclomethasone dipropionate in a new CFC-free propellant system in asthmatic patients
5. Autoradiographic localization of autonomic receptors in airway smooth muscle
6. Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs
7. Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine dose response
8. Enantioselective disposition of albuterol in humans
9. Lung gene therapy: In vivo adenovirus mediated gene transfer to rhesus monkey airway epithelium
10. Mechanisms of particle deposition and clearance
11. Physicochemical effects on lung disposition of pharmaceutical aerosols
12. Drug delivery via the respiratory tract
13. Aerosol and intravenous transfection of human α-1 antitrypsin gene to lungs of rabbits
14. Studies of cyclodextrin inclusion complexes: The pulmonary absorption of salbutamol from a complex with 2-hydroxypropyl-β-cyclodextrin in rabbits
15. The influence of regional deposition on the pharmacokinetics of pulmonary delivered human growth hormone in rabbits
16. Drug targeting to the lung: Chemical and biochemical considerations
17. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
18. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose
19. Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol
20. New propellant free technologies under investigation
21. Optimization of formulations and conditions for the aerosol delivery of functional cationic lipid: DNA complexes
22. Large porous particles for pulmonary drug delivery
23. Controlled-release inhalation aerosols
24. Recent advances in pulmonary drug delivery using large, porous inhaled particles
25. Survey of the clinical use of pressurized aerosol inhalers
26. Bitolterol: A preliminary review of its pharmacological properties and therapeutic efficacy in reversible obstructive airway disease
27. Targeted delivery of inhaled drugs: Current challenges and future goals
28. The effect of regular inhaled albuterol on allergen induced late response and sputum eosinophils in asthmatic subjects
29. Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract
30. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma
31. Contemporary approaches in aerosolized drug delivery to the lung
32. Modulated-release aerosol
33. Preclinical and metabolic profiles of (R,R)-erformoterol
34. Pharmacokinetics and dose proportionality of beclomethasone from three strengths of a CFC-free beclomethasone dipropionate metered-dose inhaler
35. Medication nebulizer performance: Effects of diluent volume, nebulizer flow and nebulizer brand
36. Biodegradable polymers for controlled release of peptides and proteins
37. Preparation, characterization, and dissolution kinetics of two novel albuterol salts
38. Clinical evaluation of CFC-free metered-dose inhalers
39. Effects of eformoterol enantiomers on in vitro bronchial reactivity
40. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis
41. Gene therapy for lung disease: Molecular and clinical therapeutic issues
42. Health related quality of life in asthma: 400 μg of hydrofluoroalkane beclomethasone dipropionate versus 800 μg chlorofluorocarbon beclomethasone dipropionate
43. An interaction between reactions of guinea pig airways to antigen and to (S)-albuterol
44. Size aspects of metered-dose inhaler aerosols
45. Particle transport from the lower respiratory tract
46. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone
47. Pulmonary absorption of therapeutic peptides and proteins
48. 2-selective sympathomimetics
49. (S)-albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C dependent mechanism in airway smooth muscle
50. Anomalous effects of albuterol and other sympathomimetics in the guinea-pig
51. Improved bronchodilation with leval-buterol compared with racemic albuterol in patients with asthma
52. Tennis anyone? The lungs as a new court for systemic therapy
53. How should a pressurized β-adrenergic bronchodilator be inhaled?
54. Aerosol deposition considerations in inhalation therapy
55. Modulated drug therapy with inhalation aerosols
56. Effects of formulation on gene delivery to the lungs
57. Chlorofluorocarbon-free inhalers: Are we ready for the change?
58. Pulmonary absorption and metabolism of peptides and proteins
59. Maximization of pulmonary hygroscopic aerosol deposition
60. Absorption and bioavailability of inhaled peptides and proteins
61. The effects of preferential deposition of histamine in the human airway
62. Standardization of inhalation provocation tests: Two techniques of aerosol generation and inhalation compared
63. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics
64. Pharmacokinetics and pharmacodynamics of bambuterol, a long-lasting bronchodilator pro-drug of terbutaline, in young and elderly patients with asthma
65. Deposition pattern of droplets from medical nebulizers in the human respiratory tract
66. 2 receptor antagonist inhaler
67. Extra-fine corticosteroid aerosols from hydrofluoroalkane-134a metered-dose inhalers: Potential advantages and disadvantages
68. The influence of liposome encapsulation on sodium cromoglycate pharmacokinetics in man
69. Effects of S-salbutamol on human isolated bronchus
70. From Susie's question to CFC free: An inventor's perspective on forty years of MDI development and regulation
71. Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol
72. Pro- and anti-inflammatory effects of β-adrenergic agonists on eosinophil response to IL-5
73. Pulmonary delivery of anti-inflammatory glucocorticoids and immunosuppressive cyclosporin-A by liposome aerosols
74. Human cystic fibrosis transmembrane conductance regulator directed to respiratory epithelial cells of transgenic mice
75. Liquid and protein clearance from the lung
76. Cystic fibrosis: Strategies for gene therapy
77. Human Mn-superoxide dismutase in pulmonary epithelial cells of transgenic mice confers protection from oxygen injury
78. (S)-albuterol exacerbates calcium responses to carbachol in airway smooth muscle cells
79. 2 agonist and anticholinergic aerosols in patients with severe airway obstruction
80. The efficacy of a low-dose, monodisperse parasympatholytic aerosol compared with a standard aerosol from a metered-dose inhaler
81. The controlled delivery of drugs to the lung